FDG-PET/CT in Lymphoma: Where Do We Go Now? - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Cancers Year : 2021

FDG-PET/CT in Lymphoma: Where Do We Go Now?


18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is an essential part of the management of patients with lymphoma at staging and response evaluation. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma but also points out the potential place of innovative PET/CT metrics or new radiopharmaceuticals in the future.


Fichier principal
Vignette du fichier
cancers-13-05222-v2.pdf (1.11 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03540811 , version 1 (24-01-2022)



Yassine Al Tabaa, Clement Bailly, Salim Kanoun. FDG-PET/CT in Lymphoma: Where Do We Go Now?. Cancers, 2021, 13 (20), pp.5222. ⟨10.3390/cancers13205222⟩. ⟨inserm-03540811⟩
18 View
104 Download



Gmail Facebook X LinkedIn More